


## Hedgehog IN-6

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-162372   |
| <b>Molecular Formula:</b> | C <sub>25</sub> H <sub>43</sub> NO <sub>2</sub>   |
| <b>Molecular Weight:</b>  | 389.61  |
| <b>Target:</b>            | Hedgehog; Smo   |
| <b>Pathway:</b>           | Stem Cell/Wnt   |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                    |  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
|--------------------|--|---------------|---------------------------------|----------------|-------------|------------------|------|---------|--|------------|-----------------------------------|----------------|-------------|------------------|----------|---------|--|
| <b>Description</b> | Hedgehog IN-6 (Compound Q29) is a Hedgehog (Hh) inhibitor that can be used in cancer research. Hedgehog IN-6 inhibits the hedgehog (Hh) pathway by binding to the cysteine-rich domain (CRD) of Smoothened (Smo) and blocking its cholesterization <sup>[1]</sup> .  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| <b>In Vitro</b>    | <p>Q29 (1-10 μM; 24 h) dose-dependently inhibits GLI1 protein expression activated by Shh-N<sup>[1]</sup>.</p> <p>Q29 (1-10 μM; 24 h + 12 h) inhibits Hh signaling-dependent cell proliferation in a dose-dependent manner<sup>[1]</sup>.</p> <p>Q29 inhibits Gli-luciferase activity with an IC<sub>50</sub> of 1.33 μM in the presence of different concentrations of Shh-N<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>NIH 3T3 cells</td> </tr> <tr> <td>Concentration:</td> <td>1, 3, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Dose dependently decreased the protein and mRNA levels of endogenous Gli1.</td> </tr> </table> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>cGNP cells; medulloblastoma cells</td> </tr> <tr> <td>Concentration:</td> <td>1, 3, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h+12h</td> </tr> <tr> <td>Result:</td> <td>Dose dependently inhibited the growth of Shh-N-stimulated cGNP cells and medulloblastoma cells isolated from Ptch1+/P53/ mice.</td> </tr> </table> | Cell Line:    | NIH 3T3 cells                   | Concentration: | 1, 3, 10 μM | Incubation Time: | 24 h | Result: | Dose dependently decreased the protein and mRNA levels of endogenous Gli1. | Cell Line: | cGNP cells; medulloblastoma cells | Concentration: | 1, 3, 10 μM | Incubation Time: | 24 h+12h | Result: | Dose dependently inhibited the growth of Shh-N-stimulated cGNP cells and medulloblastoma cells isolated from Ptch1+/P53/ mice. |
| Cell Line:         | NIH 3T3 cells  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Concentration:     | 1, 3, 10 μM  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Incubation Time:   | 24 h   |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Result:            | Dose dependently decreased the protein and mRNA levels of endogenous Gli1.   |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Cell Line:         | cGNP cells; medulloblastoma cells  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Concentration:     | 1, 3, 10 μM  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Incubation Time:   | 24 h+12h   |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Result:            | Dose dependently inhibited the growth of Shh-N-stimulated cGNP cells and medulloblastoma cells isolated from Ptch1+/P53/ mice.   |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| <b>In Vivo</b>     | <p>Q29 (90 mg/kg; oral gavage; twice daily; 13 days) effectively inhibits tumor growth in Ptch1+/P53/ mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Ptch1+/P53/ mice<sup>[1]</sup></td> </tr> </table>   | Animal Model: | Ptch1+/P53/ mice <sup>[1]</sup> |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |
| Animal Model:      | Ptch1+/P53/ mice <sup>[1]</sup>  |               |                                 |                |             |                  |      |         |  |            |                                   |                |             |                  |          |         |  |

---

|                 |  |
|-----------------|--|
| Dosage:         | 90 mg/kg   |
| Administration: | p.o.; twice daily; 13 days   |
| Result:         | Effectively inhibited tumor growth and exhibited synergistic inhibition with vismodegib (15 mg/kg; HY-10440) |

---

## REFERENCES

---

[1]. Liu YB, et al. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened. Cell Chem Biol. 2024 Feb 28;S2451-9456(24)00076-X.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA